EyePoint Pharmaceuticals 将来の成長

Future 基準チェック /26

EyePoint Pharmaceuticalsの収益は年間1%で減少すると予測されていますが、年間収益は年間44.8%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-81.8% 5%なると予測されています。

主要情報

-1.0%

収益成長率

5.0%

EPS成長率

Pharmaceuticals 収益成長	24.0%
収益成長率	44.8%
将来の株主資本利益率	-81.8%
アナリストカバレッジ	Good
最終更新日	18 Dec 2024

今後の成長に関する最新情報

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09

Recent updates

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk

Dec 13

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

Oct 29

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

Sep 13

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Aug 15

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06

業績と収益の成長予測

NasdaqGM:EYPT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8	-217	-152	-190	8
12/31/2025	15	-178	-137	-158	11
12/31/2024	42	-120	-130	-106	11
9/30/2024	46	-104	-118	-113	N/A
6/30/2024	50	-87	-94	-90	N/A
3/31/2024	50	-79	-17	-12	N/A
12/31/2023	46	-71	-2	2	N/A
9/30/2023	43	-100	9	12	N/A
6/30/2023	37	-106	12	14	N/A
3/31/2023	40	-102	-64	-62	N/A
12/31/2022	41	-102	-67	-65	N/A
9/30/2022	42	-78	-71	-69	N/A
6/30/2022	41	-77	-64	-64	N/A
3/31/2022	39	-67	-55	-55	N/A
12/31/2021	37	-58	-50	-50	N/A
9/30/2021	33	-54	-28	-28	N/A
6/30/2021	39	-42	-19	-19	N/A
3/31/2021	34	-44	-14	-13	N/A
12/31/2020	34	-45	-15	-14	N/A
9/30/2020	36	-40	-32	-32	N/A
6/30/2020	23	-52	-48	-48	N/A
3/31/2020	26	-51	-60	-60	N/A
12/31/2019	20	-57	-57	-57	N/A
9/30/2019	14	-58	-56	-56	N/A
6/30/2019	12	-75	-53	-53	N/A
3/31/2019	6	-98	-42	-42	N/A
12/31/2018	5	-86	-34	-33	N/A
9/30/2018	3	-80	-28	-28	N/A
6/30/2018	3	-53	N/A	-22	N/A
3/31/2018	3	-25	N/A	-20	N/A
12/31/2017	3	-23	N/A	-20	N/A
9/30/2017	8	-17	N/A	-20	N/A
6/30/2017	8	-18	N/A	-20	N/A
3/31/2017	7	-19	N/A	-20	N/A
12/31/2016	7	-19	N/A	-20	N/A
9/30/2016	1	-24	N/A	-18	N/A
6/30/2016	2	-22	N/A	-16	N/A
3/31/2016	2	-20	N/A	-15	N/A
12/31/2015	2	-20	N/A	-15	N/A
9/30/2015	2	-19	N/A	10	N/A
6/30/2015	27	6	N/A	10	N/A
3/31/2015	26	8	N/A	11	N/A
12/31/2014	28	10	N/A	13	N/A
9/30/2014	28	11	N/A	-11	N/A
6/30/2014	3	-13	N/A	-11	N/A
3/31/2014	4	-13	N/A	-11	N/A
12/31/2013	2	-14	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EYPT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: EYPT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: EYPT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: EYPTの収益 ( 44.8% ) US市場 ( 9.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: EYPTの収益 ( 44.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EYPT 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/30 23:19
終値	2024/12/30 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

EyePoint Pharmaceuticals, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。19

アナリスト	機関
Colleen Kusy	Baird
Andrew D'Silva	B. Riley Securities, Inc.
Jennifer Kim	Cantor Fitzgerald & Co.

EyePoint Pharmaceuticals 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus revenue estimates fall by 18%

Price target increased by 28% to US$39.29

Consensus revenue estimates increase by 19%

Consensus revenue estimates increase by 13%

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Recent updates

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk

Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema

Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of Durasert for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

EyePoint Pharmaceuticals, Inc. Announces Board Changes

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

New major risk - Revenue and earnings growth

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Management Changes

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Executive Vice-Chairman exercised options and sold US$430k worth of stock

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Senior VP & Chief Medical Officer exercised options and sold US$621k worth of stock

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Executive Vice-Chairman recently sold US$874k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Executive Vice-Chairman exercised options and sold US$470k worth of stock

EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Executive Vice-Chairman recently sold US$415k worth of stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Senior VP & Chief Medical Officer notifies of intention to sell stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Price target increased by 28% to US$39.29

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

EyePoint Pharmaceuticals, Inc. Announces Executive Changes

EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901

EyePoint Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Consensus revenue estimates increase by 19%

Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy

Consensus revenue estimates increase by 13%

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Full year 2022 earnings: EPS misses analyst expectations

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind